


## "Patient-centric design for systemic peptide delivery: Trends in routes of administration and advancement in drug delivery technologies"

Manuel Sanchez-Felix

Novartis Institutes for BioMedical Research, Cambridge, MA, USA

Utilizing peptides as therapeutic agents is considered an attractive approach for the treatment of various diseases due to their high binding and selectivity to novel drug targets. However, the physicochemical properties of peptides make them challenging to administer exogenously, which places a high burden on drug delivery technology selection to successfully achieve the desired response. Various peptide drug delivery systems have been used in clinical and marketed products to overcome the problems associated with exogenous administration of peptide therapeutics. This review details the trends observed pertaining to the delivery of peptides such as changes in the routes of administration, advancements in formulation platforms, patient-centric product design, and various other aspects of peptide delivery.



- [1] Wenzhan Yang, Prajakta Gadgil, Venkata R. Krishnamurthy, Margaret Landis, Pankajini Mallick, Dipal Patel, Phenil J. Patel, Darren L. Reid & Manuel Sanchez-Felix, *The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules*, *The AAPS Journal* volume 22, Article number: 21 (2020)
- [2] Ahil N.Ganesh, Carolyn Heusser, Sudhakar Garad, Manuel Vicente Sánchez-Félix, *Patient-centric design for peptide delivery: Trends in routes of administration and advancement in drug delivery technologies*, *Medicine in Drug Discovery*, Volume 9, March 2021,
- [3] Manuel Sánchez-Félix, Matt Burke, Hunter H Chen, Claire Patterson, Sachin Mittal, *Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge*, *Adv Drug Deliv Rev*, 2020